No Data
No Data
Protara Therapeutics Shares Positive Phase 2 Interim Results Of TARA-002 In Patients With NMIBC
Express News | Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 Advanced-2 Trial of Tara-002 in Patients With Nmibc
Protara Therapeutics Shares Are Trading Higher After the Company Announced It Will Review the Interim Data From Its Phase 2 ADVANCED-2 Trial.
Express News | Protara Therapeutics Shares Are Trading Higher After the Company Announced It Will Review the Interim Data From Its Phase 2 ADVANCED-2 Trial
Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data From Phase 2 ADVANCED-2 Trial of TARA-002 in Patients With NMIBC on Monday, April 28, 2025
This H.B. Fuller Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday